Adaptive Platform Treatment Trial for Outpatients with COVID-19 (ACTIV-2)
Outpatient Treatment for COVID-19 (ACTIV-2)
Sponsor: National Institute of Allergy and Infectious Diseases NIAID
Enrolling: Male and Female Patients
Study Length: 18 Months
Clinic Visits: 11
IRB Number: AAAT6083
U.S. Govt. ID: NCT04518410
Contact: Bronx Prevention Center: 347-590-7280 /
Additional Study Information: This study enrolls people recently diagnosed with COVID-19, who are not currently in the hospital. The study tests several different investigational medicines to see if they are safe and can help adults with COVID-19 get better, with the goal of quickly determining those that are safe and effective. Help us to rise above COVID-19!
This study is closed
Ellen Morrison, MD, MPH
Do You Qualify?
Are you having any symptoms of COVID-19 (i.e., fever, body aches, chills, loss of taste/smell, etc.)? Yes No
Have you been hospitalized for COVID-19? Yes No
Are you pregnant or breastfeeding? If N/A, select No. Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Bronx Prevention Center